Abstract Background Aberrant activation of the IL-4/IL-13-STAT6 axis drives Th2-mediated inflammatory diseases. As the key and specific transcription factor downstream of IL-4Rα, STAT6 represents a highly selective and clinically validated target. Biologic therapies such as Dupilumab have confirmed the therapeutic value but are limited by injectable delivery. SIM0712 is a novel, potent, and selective oral STAT6 PROTAC designed to achieve complete STAT6 degradation, enabling more potent pathway inhibition and broader clinical utility. This study summarizes the in vitro and in vivo pharmacology, pharmacodynamics, and safety data supporting SIM0712’s advancement toward clinical development. Methods STAT6 degradation and downstream pathway inhibition were evaluated in human immune cells as well as stromal cell lines. Functional assays assessed IL-4/IL-13 induced pSTAT6, CCL17 release, and CD23 expression. In vitro ADME studies included solubility, permeability, CYP inhibition, and stability. In vivo PK/PD profiling was characterized following single oral doses in mouse, rat, dog, and cynomolgus monkey. In vivo efficacy was examined in an house dust mite induced (HDM) allergic asthma mouse model. Results SIM0712 induced rapid, potent, and near-complete STAT6 degradation in human PBMCs within hours, with robust degradation also observed across immune cell subsets, keratinocyte, and epithelial cell lines, as well as PBMCs in multiple species. STAT6 degradation led to complete inhibition of IL-4/IL-13 induced pSTAT6 without affecting other STAT family members, demonstrating high pathway selectivity. Functionally, SIM0712 fully suppressed IL-4/IL-13 induced CCL17 release by PBMCs and CD23 expression in B cells with superior potency to Dupilumab, confirming deep Th2 pathway blockade. In vivo, single oral administration of SIM0712 resulted in dose-dependent STAT6 degradation across species. In an HDM induced asthma model, oral SIM0712 produced Dupilumab-like efficacy, significantly reducing airway inflammation. In vitro ADME profiling demonstrated favorable solubility, permeability, and metabolic stability with no CYP inhibition. Safety profiling showed no significant off-target activity across proteomics, kinase, and safety panels, and SIM0712 was well tolerated in 28-day rat DRF studies. Conclusions SIM0712 is a highly potent and selective oral STAT6 degrader achieving complete IL-4/IL-13 pathway blockade with favorable PK/PD and safety profiles. These findings support its development as a novel oral therapy for Th2-driven inflammatory and allergic diseases, with IND submission planned for H2 2026. This abstract is funded by: None
Zhou et al. (Fri,) studied this question.